pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

4,011 catalysts · 4,728 grant · 3,912 device 510k · 3,080 8k filing · 3,076 approval · 2,000 device pma · 2,000 device recall

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 0 catalysts2026-08-11: 51 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 12 catalysts2026-10-29: 21 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 9 catalysts2026-11-03: 18 catalysts2026-11-04: 22 catalysts2026-11-05: 37 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
sort
soonestlatesttypesponsoralpha
type: approval×type: recall×from 2025-01-24×clear all
type
  • grant4,728
  • device 510k3,912
  • 8k filing3,080
  • approval3,076
  • device pma2,000
  • device recall2,000
device adverse event
1,000
  • recall935
  • earnings583
  • phase 2 completion172
  • therapy area

    no tagged catalysts yet

    Week of Jan 20, 2025

    5
    ›Jan 24, 2025approval565d agoMEKINIST (TRAMETINIB) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: SOLUTION. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Jan 24, 2025approval565d agoMEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalSpexotras

    Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

    full page →Spexotras →fda approvals ↗
    ›Jan 24, 2025approval565d agoLEQEMBI (LECANEMAB-IRMB) — FDA approvallecanemab

    Sponsor: EISAI INC. Form: INJECTABLE. Route: INJECTION

    full page →lecanemab →fda approvals ↗
    ›Jan 24, 2025approval565d agoAVTOZMA (TOCILIZUMAB-ANOH) — FDA approvalAVTOZMA

    Sponsor: CELLTRION INC. Form: INJECTABLE. Route: INTRAVENOUS

    full page →AVTOZMA →fda approvals ↗
    ›Jan 26, 2025approval563d agoNIZORAL ANTI-DANDRUFF (KETOCONAZOLE) — FDA approvalTeva Pharmaceuticals USA Inc

    Sponsor: KRAMER. Form: SHAMPOO. Route: TOPICAL

    full page →fda approvals ↗

    Week of Jan 27, 2025

    28
    ›Jan 27, 2025approval562d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: TORRENT PHARMS. Form: TABLET, CHEWABLE. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 27, 2025approval

    Week of Feb 3, 2025

    14
    ›Feb 3, 2025approval555d agoVALPROIC ACID — FDA approvalCereno Scientific AB

    Sponsor: CHARTWELL RX. Form: SYRUP. Route: ORAL

    full page →fda approvals ↗
    ›Feb 4, 2025approval

    Week of Feb 10, 2025

    3
    ›Feb 10, 2025approval548d agoENZEEVU (AFLIBERCEPT-ABZV) — FDA approvalaflibercept biosimilar

    Sponsor: SANDOZ INC. Form: INJECTABLE. Route: INJECTION

    full page →aflibercept biosimilar →fda approvals ↗
    ›Feb 11, 2025approval
    ← prev
    page 1 of 81
    next →
    562d ago
    CARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: TORRENT PHARMS. Form: TABLET. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 27, 2025approval562d agoCARBAMAZEPINE — FDA approvalcarbamazepine ER

    Sponsor: TORRENT PHARMS. Form: TABLET. Route: ORAL

    full page →carbamazepine ER →fda approvals ↗
    ›Jan 27, 2025approval562d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›Jan 27, 2025approval562d agoENHERTU (FAM-TRASTUZUMAB DERUXTECAN-NXKI) — FDA approvaltrastuzumab deruxtecan

    Sponsor: DAIICHI SANKYO. Form: INJECTABLE. Route: INJECTION

    full page →trastuzumab deruxtecan →fda approvals ↗
    ›Jan 28, 2025approval561d agoKEYTRUDA (PEMBROLIZUMAB) — FDA approvalpembrolizumab

    Sponsor: MERCK SHARP DOHME. Form: SOLUTION. Route: INTRAVENOUS

    full page →pembrolizumab →fda approvals ↗
    ›Jan 28, 2025approval561d agoEPYSQLI (ECULIZUMAB-AAGH) — FDA approvalEPYSQLI

    Sponsor: SAMSUNG BIOEPIS CO LTD. Form: INJECTION. Route: SOLUTION

    full page →EPYSQLI →fda approvals ↗
    ›Jan 28, 2025approval561d agoOZEMPIC (SEMAGLUTIDE) — FDA approvalNovo Nordisk AS

    Sponsor: NOVO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Jan 29, 2025approval560d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: TEVA PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 29, 2025approval560d agoOLANZAPINE AND FLUOXETINE HYDROCHLORIDE (FLUOXETINE HYDROCHLORIDE) — FDA approvalEpic Pharma LLC

    Sponsor: TEVA PHARMS. Form: CAPSULE. Route: ORAL

    full page →fda approvals ↗
    ›Jan 29, 2025approval560d agoOXYMORPHONE HYDROCHLORIDE — FDA approvalOXYMORPHONE HYDROCHLORIDE

    Sponsor: AVANTHI INC. Form: TABLET. Route: ORAL

    full page →OXYMORPHONE HYDROCHLORIDE →fda approvals ↗
    ›Jan 29, 2025approval560d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: ABHAI LLC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jan 29, 2025approval560d agoHYDROCODONE BITARTRATE AND ACETAMINOPHEN (ACETAMINOPHEN) — FDA approvalacetaminophen ER

    Sponsor: ABHAI LLC. Form: TABLET. Route: ORAL

    full page →acetaminophen ER →fda approvals ↗
    ›Jan 29, 2025approval560d agoBUPROPION HYDROCHLORIDE — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: ALEMBIC. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Jan 29, 2025recall560d agoBrands International Corporation recall (Cls II)

    Kissable Diabetics Foot Cream, NET WT 4 oz (113 g) per tube, Manufactured By: Brands International Corp., Newmarket, ON, L3X 2S2. UPC 6 72008 80925 3 — Reason: CGMP Deviations: lack of adequate release testing. — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 29, 2025recall560d agoFirst Aid Beauty Ltd recall (Cls II)

    First Aid Beauty Ultra Repair Cream, colloidal oatmeal 0.5%, Coconut Vanilla, Net Wt. 396.8 g (14 OZ), DISTR. BY: First Aid Beauty LTD, Newton, MA, 02458, UPC 8 15517 02955 6 — Reason: CGMP Deviations; product intended for quarantine was inadvertently distributed — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 29, 2025recall560d agoSHOPPERS- PLAZA recall (Cls I)Eton Pharmaceuticals, Inc.

    FOUZEE SugarLin HERBAL FORMULA capsules, 180 capsules per bottle, Sold and Distributed by Shoppers-Plaza, Hawthorne, CA 90250. Product of India. UPC 8 26656 69047 7 — Reason: Marketed without an Approved NDA/ANDA; FDA laboratory analysis confirmed product tainted with undeclared metformin and glyburide — Status: Ongoing

    full page →fda recalls ↗
    ›Jan 29, 2025recall560d agoAppco Pharma LLC recall (Cls III)Appco Pharma LLC

    Venlafaxine Extended-Release Tablets, 150mg, Rx only, 90 Tablets, Manufactured by Appco Pharma. LLC, NDC 43598-943-90. — Reason: Failed Tablet/Capsule Specifications: Missing tab ID on either side of the tablet — Status: Completed

    full page →fda recalls ↗
    ›Jan 30, 2025approval559d agoBKEMV (ECULIZUMAB-AEEB) — FDA approvaleculizumab biosimilar

    Sponsor: AMGEN INC. Form: INJECTABLE. Route: INJECTION

    full page →eculizumab biosimilar →fda approvals ↗
    ›Jan 30, 2025approval559d agoTAFINLAR (DABRAFENIB MESYLATE) — FDA approvaldabrafenib mesylate ODT

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →dabrafenib mesylate ODT →fda approvals ↗
    ›Jan 30, 2025approval559d agoTAFINLAR (DABRAFENIB MESYLATE) — FDA approvaldabrafenib mesylate ODT

    Sponsor: NOVARTIS. Form: CAPSULE. Route: ORAL

    full page →dabrafenib mesylate ODT →fda approvals ↗
    ›Jan 30, 2025approval559d agoJOURNAVX (SUZETRIGINE) — FDA approvalsuzetrigine

    Sponsor: VERTEX PHARMS INC. Form: TABLET. Route: ORAL

    full page →suzetrigine →fda approvals ↗
    ›Jan 30, 2025approval559d agoBUPRENORPHINE HYDROCHLORIDE — FDA approvalBUPRENORPHINE HYDROCHLORIDE

    Sponsor: SOMERSET THERAPS LLC. Form: INJECTABLE. Route: INJECTION

    full page →BUPRENORPHINE HYDROCHLORIDE →fda approvals ↗
    ›Jan 31, 2025approval558d agoSOGROYA (SOMAPACITAN-BECO) — FDA approvalsomatriptan albumin bound LA

    Sponsor: NOVO NORDISK INC. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →somatriptan albumin bound LA →fda approvals ↗
    ›Jan 31, 2025approval558d agoPAXLOVID (COPACKAGED) (NIRMATRELVIR) — FDA approvalPAXLOVID (COPACKAGED)

    Sponsor: PFIZER. Form: TABLET. Route: ORAL

    full page →PAXLOVID (COPACKAGED) →fda approvals ↗
    ›Jan 31, 2025approval558d agoTRAMADOL HYDROCHLORIDE — FDA approvaltramadol hydrochloride ER

    Sponsor: MACLEODS PHARMS LTD. Form: TABLET, EXTENDED RELEASE. Route: ORAL

    full page →tramadol hydrochloride ER →fda approvals ↗
    ›Jan 31, 2025approval558d agoUNASYN (AMPICILLIN SODIUM) — FDA approvalUNASYN

    Sponsor: PFIZER. Form: INJECTABLE. Route: INJECTION

    full page →UNASYN →fda approvals ↗
    ›Jan 31, 2025approval558d agoPEPCID COMPLETE (CALCIUM CARBONATE) — FDA approvalKenvue Inc.

    Sponsor: KENVUE BRANDS. Form: TABLET, CHEWABLE. Route: ORAL

    full page →fda approvals ↗
    554d ago
    GABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Feb 4, 2025approval554d agoGABAPENTIN — FDA approvalGABAPENTIN

    Sponsor: STRIDES PHARMA. Form: CAPSULE. Route: ORAL

    full page →GABAPENTIN →fda approvals ↗
    ›Feb 5, 2025approval553d agoBOSENTAN — FDA approvalBOSENTAN

    Sponsor: NATCO PHARMA LTD. Form: TABLET, FOR SUSPENSION. Route: ORAL

    full page →BOSENTAN →fda approvals ↗
    ›Feb 5, 2025approval553d agoRIFATER (ISONIAZID) — FDA approvalRIFATER

    Sponsor: SANOFI AVENTIS US. Form: TABLET. Route: ORAL

    full page →RIFATER →fda approvals ↗
    ›Feb 5, 2025approval553d agoWELLBUTRIN (BUPROPION HYDROCHLORIDE) — FDA approvalBUPROPION HYDROCHLORIDE

    Sponsor: GLAXOSMITHKLINE. Form: TABLET. Route: ORAL

    full page →BUPROPION HYDROCHLORIDE →fda approvals ↗
    ›Feb 5, 2025recall553d agoThe W.S. Badger Company, Inc. recall (Cls III)

    BADGER 50, ADVENTURE SPORT MINERAL SUNSCREEN WITH CLEAR ZINC, (uncoated 25% zinc oxide), 2.4 oz., Tin, W.S. Badger Company, Inc, 768 Route 10, Gilsum NH, 03448 UPC 6 34084 47150 2 — Reason: Labeling: Missing Label: The finished product potentially missing the labeling with the drug facts panel, bar code and directions for use. — Status: Terminated

    full page →fda recalls ↗
    ›Feb 5, 2025recall553d agoThe Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories recall (Cls II)

    Duloxetine Delayed-Release Capsules USP, 20 mg, packaged in a) 30 Unit Doses (3x10 blister packs) NDC 0904-7043-04 and b) 100 Unit Doses (10x10 blister packs) NDC 0904-7043-61, Rx only, Packaged and Distributed by: Major Pharmaceuticals, Indianapolis, IN 46268 USA. — Reason: CGMP Deviations: presence of Nitrosamine Drug Substances Related Impurity (NDSRI), N-Nitroso-Duloxetine above the FDA recommended acceptable intake limit — Status: Terminated

    full page →fda recalls ↗
    ›Feb 5, 2025recall553d agoAstellas Pharma US Inc. recall (Cls I)Astellas Pharma US Inc

    Prograf (tacrolimus) capsules, USP, 0.5 mg, 100-count bottle, Rx Only, Product of Japan, Distributed by: Astellas Pharma US, Inc., Northbrook, IL 60062, NDC 0469-0607-73. — Reason: Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 5, 2025recall553d agoMcKesson recall (Cls II)MCKESSON CORP

    Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01 — Reason: cGMP Deviations: Product intended for quarantine was inadvertently distributed. — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 5, 2025recall553d agoAstellas Pharma US Inc. recall (Cls I)Astellas Pharma US Inc

    Astagraf XL (tacrolimus extended-release capsules) 0.5 mg, 30-count bottles, RX Only, Product of Japan, Distributed by: Astellas Pharma US Inc., Northbrook, IL 60062, NDC 0469-0647-73. — Reason: Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules — Status: Ongoing

    full page →fda recalls ↗
    ›Feb 6, 2025approval552d agoFLUOROURACIL — FDA approvalExtrovis AG

    Sponsor: KINDOS. Form: INJECTABLE. Route: INJECTION

    full page →fda approvals ↗
    ›Feb 7, 2025approval551d agoZEPBOUND (TIRZEPATIDE) — FDA approvalZEPBOUND

    Sponsor: ELI LILLY AND CO. Form: SOLUTION. Route: SUBCUTANEOUS

    full page →ZEPBOUND →fda approvals ↗
    ›Feb 7, 2025approval551d agoONGENTYS (OPICAPONE) — FDA approvalopicapone

    Sponsor: AMNEAL. Form: CAPSULE. Route: ORAL

    full page →opicapone →fda approvals ↗
    547d ago
    CAMCEVI KIT (LEUPROLIDE MESYLATE) — FDA approvalForesee Pharmaceuticals Co Ltd

    Sponsor: ACCORD. Form: EMULSION. Route: SUBCUTANEOUS

    full page →fda approvals ↗
    ›Feb 11, 2025approval547d agoEVRYSDI (RISDIPLAM) — FDA approvalEVRYSDI

    Sponsor: GENENTECH INC. Form: TABLET. Route: ORAL

    full page →EVRYSDI →fda approvals ↗
    $NVS156.79+0.29%
    $NVS156.79+0.29%
    $NVS156.79+0.29%
    $AMGN417.20+1.52%
    $VERX12.13+1.63%
    $NVS156.79+0.29%
    $PFE27.05+1.08%
    $NVO47.73+0.99%
    $ETON43.67-2.09%
    $AVTR13.73+1.03%
    $KVUE19.03-1.04%
    $PFE27.05+1.08%
    $NSRX2.7000-1.82%
    $LLY1231.94+3.90%
    $MCK879.87+1.18%
    $AMRX17.88-1.43%